eculizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4969 219685-50-4

Description:

MoleculeDescription

Synonyms:

  • eculizumab
  • soliris
  • h5G1.1
  • h5G1.1VHC+h5G1.1VLC
a recombinant humanized monoclonal IgG2/4k antibody produced by murine myeloma cell culture, specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
64 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 20, 2007 EMA
March 16, 2007 FDA ALEXION PHARM
April 16, 2010 PMDA Alexion Pharma

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haemolysis 504.65 18.00 140 13203 6628 63469051
Haemoglobin decreased 443.94 18.00 311 13032 145174 63330505
Blood lactate dehydrogenase increased 315.99 18.00 134 13209 22982 63452697
Thrombotic microangiopathy 271.97 18.00 97 13246 10464 63465215
Haemoglobinuria 189.32 18.00 35 13308 240 63475439
Meningococcal sepsis 158.49 18.00 23 13320 18 63475661
Platelet count decreased 151.04 18.00 152 13191 115970 63359709
Exposure during pregnancy 133.84 18.00 164 13179 155383 63320296
Suspected COVID-19 124.35 18.00 38 13305 2524 63473155
Chromaturia 111.07 18.00 59 13284 16658 63459021
Breakthrough haemolysis 96.44 18.00 14 13329 11 63475668
Meningococcal bacteraemia 92.16 18.00 13 13330 6 63475673
Renal transplant failure 91.43 18.00 23 13320 739 63474940
Reticulocyte count increased 90.67 18.00 24 13319 946 63474733
Extravascular haemolysis 88.24 18.00 16 13327 97 63475582
Incorrect dose administered 84.35 18.00 82 13261 59886 63415793
Aplastic anaemia 81.67 18.00 40 13303 9529 63466150
Renal impairment 77.23 18.00 94 13249 88261 63387418
Transfusion 69.41 18.00 42 13301 15175 63460504
Inappropriate schedule of product administration 68.15 18.00 96 13247 103869 63371810
Haptoglobin decreased 67.48 18.00 18 13325 731 63474948
Arteriovenous fistula occlusion 63.66 18.00 15 13328 364 63475315
Off label use 61.64 18.00 292 13051 674170 62801509
Gonorrhoea 61.43 18.00 12 13331 114 63475565
Poor venous access 60.30 18.00 38 13305 14747 63460932
Polyomavirus-associated nephropathy 59.23 18.00 20 13323 1828 63473851
Headache 59.18 18.00 276 13067 632965 62842714
Meningitis meningococcal 57.78 18.00 11 13332 90 63475589
Blue toe syndrome 57.46 18.00 14 13329 393 63475286
Cytomegalovirus infection 57.18 18.00 42 13301 20910 63454769
Proteinuria 53.65 18.00 39 13304 19106 63456573
Blood lactate dehydrogenase abnormal 53.46 18.00 13 13330 362 63475317
Blood creatinine increased 52.99 18.00 78 13265 87766 63387913
Myasthenia gravis crisis 49.44 18.00 13 13330 499 63475180
Dyspnoea exertional 49.20 18.00 62 13281 60240 63415439
Condition aggravated 48.83 18.00 190 13153 402027 63073652
Nephrectomy 47.07 18.00 16 13327 1492 63474187
Haemoglobin abnormal 45.61 18.00 22 13321 5066 63470613
Total complement activity decreased 44.81 18.00 6 13337 0 63475679
Gonococcal infection 44.81 18.00 6 13337 0 63475679
Drug intolerance 44.72 18.00 6 13337 308655 63167024
Platelet count abnormal 44.25 18.00 19 13324 3345 63472334
Anaemia 42.64 18.00 147 13196 293283 63182396
Transplant rejection 42.20 18.00 27 13316 10753 63464926
Plasmapheresis 40.93 18.00 10 13333 284 63475395
Atypical haemolytic uraemic syndrome 40.39 18.00 12 13331 723 63474956
Cervicitis 40.10 18.00 11 13332 497 63475182
Jaundice 39.24 18.00 39 13304 29212 63446467
Sepsis 39.09 18.00 94 13249 153029 63322650
Bacteraemia 39.03 18.00 31 13312 17317 63458362
Pre-eclampsia 38.56 18.00 24 13319 9109 63466570
Iron overload 38.12 18.00 12 13331 879 63474800
Pneumonia bacterial 37.78 18.00 24 13319 9441 63466238
Total complement activity increased 37.34 18.00 5 13338 0 63475679
Renal transplant 36.73 18.00 13 13330 1367 63474312
Drug hypersensitivity 36.65 18.00 10 13333 310677 63165002
SARS-CoV-2 test positive 36.13 18.00 22 13321 8034 63467645
Cytomegalovirus gastrointestinal infection 35.42 18.00 9 13334 301 63475378
Fatigue 35.04 18.00 311 13032 887717 62587962
Meningococcal infection 34.11 18.00 7 13336 87 63475592
Graft loss 33.77 18.00 9 13334 364 63475315
Haematocrit decreased 32.96 18.00 41 13302 39299 63436380
Premature delivery 32.78 18.00 36 13307 30245 63445434
Product use issue 32.61 18.00 4 13339 220516 63255163
Graft ischaemia 32.22 18.00 6 13337 43 63475636
Toxicity to various agents 31.01 18.00 7 13336 247243 63228436
Thrombosis 30.04 18.00 51 13292 64704 63410975
Waterhouse-Friderichsen syndrome 29.87 18.00 4 13339 0 63475679
Intravascular haemolysis 29.57 18.00 8 13335 343 63475336
Quality of life decreased 29.47 18.00 20 13323 8783 63466896
Multiple organ dysfunction syndrome 29.43 18.00 47 13296 56705 63418974
Hospitalisation 29.38 18.00 59 13284 85022 63390657
Swelling 28.69 18.00 11 13332 275367 63200312
Alopecia 28.36 18.00 18 13325 337518 63138161
Muscle strain 28.18 18.00 19 13324 8255 63467424
Babesiosis 27.91 18.00 7 13336 222 63475457
Rash 27.85 18.00 47 13296 560824 62914855
Bone marrow transplant 27.66 18.00 9 13334 733 63474946
Glossodynia 27.05 18.00 3 13340 178873 63296806
Renal pain 27.00 18.00 17 13326 6582 63469097
Haemolytic anaemia 26.95 18.00 20 13323 10105 63465574
SARS-CoV-2 test negative 26.78 18.00 8 13335 491 63475188
Pyrexia 26.36 18.00 179 13164 470299 63005380
Gastroenteritis 26.03 18.00 30 13313 26560 63449119
Delayed engraftment 26.02 18.00 6 13337 132 63475547
Complement factor abnormal 25.83 18.00 4 13339 7 63475672
Haptoglobin increased 25.74 18.00 5 13338 46 63475633
Device related infection 25.65 18.00 28 13315 23364 63452315
Joint swelling 25.49 18.00 19 13324 327647 63148032
Maternal exposure during breast feeding 25.46 18.00 14 13329 4227 63471452
Therapeutic product effect decreased 25.18 18.00 5 13338 193182 63282497
Graft thrombosis 24.96 18.00 6 13337 159 63475520
Arthritis bacterial 24.83 18.00 16 13327 6447 63469232
Abdominal discomfort 24.46 18.00 19 13324 320866 63154813
Reperfusion injury 24.09 18.00 5 13338 66 63475613
Blood product transfusion dependent 23.93 18.00 6 13337 190 63475489
Thrombocytopenia 23.91 18.00 78 13265 151079 63324600
Polyomavirus viraemia 23.75 18.00 8 13335 726 63474953
Budd-Chiari syndrome 23.68 18.00 5 13338 72 63475607
Small cell lung cancer recurrent 23.44 18.00 4 13339 16 63475663
Viral infection 23.43 18.00 33 13310 35630 63440049
Meningitis 23.30 18.00 16 13327 7161 63468518
Platelet transfusion 23.01 18.00 8 13335 798 63474881
Cytopenia 22.46 18.00 19 13324 11582 63464097
Treatment failure 22.36 18.00 7 13336 199036 63276643
Pain 21.96 18.00 81 13262 740547 62735132
Complement factor C3 decreased 21.44 18.00 6 13337 292 63475387
Dysphagia 21.11 18.00 53 13290 88532 63387147
Escherichia bacteraemia 21.08 18.00 12 13331 3871 63471808
Systemic lupus erythematosus 20.69 18.00 9 13334 208909 63266770
Serum ferritin increased 20.59 18.00 14 13329 6168 63469511
Abdominal pain 20.36 18.00 118 13225 293338 63182341
Complications of transplanted kidney 20.04 18.00 10 13333 2476 63473203
Myelodysplastic syndrome 20.03 18.00 21 13322 16733 63458946
Pregnancy 19.77 18.00 31 13312 36805 63438874
Hepatic enzyme increased 19.59 18.00 9 13334 202319 63273360
Ocular icterus 19.05 18.00 11 13332 3645 63472034
Uterine atony 18.84 18.00 5 13338 199 63475480
Red blood cell count decreased 18.83 18.00 32 13311 40613 63435066
Mucormycosis 18.69 18.00 10 13333 2861 63472818
Haematocrit abnormal 18.57 18.00 7 13336 880 63474799
Gastrointestinal mucormycosis 18.16 18.00 5 13338 229 63475450
Foetal growth restriction 18.07 18.00 14 13329 7539 63468140

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haemolysis 417.97 20.01 133 9203 7961 34939634
Haemoglobin decreased 213.61 20.01 208 9128 120564 34827031
Haemoglobinuria 213.49 20.01 46 9290 569 34947026
Blood lactate dehydrogenase increased 208.37 20.01 108 9228 22882 34924713
Thrombotic microangiopathy 193.60 20.01 81 9255 10549 34937046
Breakthrough haemolysis 93.09 20.01 14 9322 11 34947584
Chromaturia 92.23 20.01 54 9282 14466 34933129
Extravascular haemolysis 87.99 20.01 14 9322 22 34947573
Haptoglobin decreased 82.94 20.01 21 9315 541 34947054
Fatigue 77.18 20.01 245 9091 370408 34577187
Transfusion 76.73 20.01 40 9296 8545 34939050
Meningococcal sepsis 74.98 20.01 12 9324 20 34947575
Poor venous access 73.09 20.01 33 9303 5150 34942445
Incorrect dose administered 69.84 20.01 69 9267 40446 34907149
Reticulocyte count increased 68.02 20.01 18 9318 554 34947041
Suspected COVID-19 66.51 20.01 21 9315 1218 34946377
Meningococcal bacteraemia 61.75 20.01 9 9327 4 34947591
End stage renal disease 61.71 20.01 35 9301 8826 34938769
Myasthenia gravis crisis 57.14 20.01 16 9320 611 34946984
Platelet count decreased 55.75 20.01 108 9228 119609 34827986
SARS-CoV-2 test positive 51.18 20.01 27 9309 5906 34941689
Polyomavirus viraemia 50.66 20.01 16 9320 929 34946666
Haemoglobin abnormal 46.28 20.01 22 9314 3858 34943737
Meningococcal infection 44.82 20.01 7 9329 9 34947586
Staphylococcal mediastinitis 42.13 20.01 8 9328 49 34947546
Headache 39.12 20.01 130 9206 200505 34747090
Complement factor increased 38.73 20.01 6 9330 7 34947588
Renal impairment 37.69 20.01 80 9256 94433 34853162
Cytomegalovirus oesophagitis 37.53 20.01 11 9325 495 34947100
Bone marrow transplant 36.95 20.01 13 9323 1055 34946540
Jaundice 36.85 20.01 44 9292 31838 34915757
Drug interaction 36.33 20.01 8 9328 225938 34721657
Device related infection 34.69 20.01 32 9304 17205 34930390
Off label use 34.49 20.01 210 9126 419314 34528281
C3 glomerulopathy 34.02 20.01 7 9329 68 34947527
Total complement activity decreased 33.79 20.01 5 9331 3 34947592
Aplastic anaemia 32.01 20.01 24 9312 9692 34937903
Condition aggravated 31.79 20.01 118 9218 192078 34755517
Haematocrit decreased 31.68 20.01 41 9295 32175 34915420
Complement factor C3 decreased 31.16 20.01 6 9330 40 34947555
Quality of life decreased 31.12 20.01 17 9319 3984 34943611
Blood product transfusion dependent 30.95 20.01 9 9327 394 34947201
Epstein-Barr viraemia 30.76 20.01 12 9324 1300 34946295
Inappropriate schedule of product administration 29.91 20.01 57 9279 62239 34885356
Cholelithiasis 29.19 20.01 32 9304 21116 34926479
Endoscopy upper gastrointestinal tract abnormal 29.18 20.01 6 9330 58 34947537
Transplant rejection 28.59 20.01 23 9313 10288 34937307
Disseminated varicella zoster virus infection 28.38 20.01 8 9328 313 34947282
Encephalitis viral 28.11 20.01 11 9325 1201 34946394
Infection 27.45 20.01 69 9267 90846 34856749
Polyomavirus-associated nephropathy 26.26 20.01 15 9321 3829 34943766
Viral sepsis 25.63 20.01 6 9330 110 34947485
Intravascular haemolysis 25.43 20.01 8 9328 458 34947137
Multiple organ dysfunction syndrome 24.05 20.01 59 9277 76507 34871088
Graft loss 24.02 20.01 9 9327 874 34946721
Dyspnoea exertional 23.80 20.01 42 9294 43237 34904358
Brain abscess 23.54 20.01 13 9323 3112 34944483
Myelodysplastic syndrome 23.00 20.01 27 9309 19181 34928414
Abdominal pain 22.62 20.01 95 9241 163523 34784072
Nasopharyngitis 22.06 20.01 54 9282 69914 34877681
Graft versus host disease 22.00 20.01 20 9316 10549 34937046
Haptoglobin abnormal 21.69 20.01 3 9333 0 34947595
Platelet count abnormal 21.58 20.01 12 9324 2910 34944685
Renal tubular atrophy 21.55 20.01 9 9327 1163 34946432
Meningitis meningococcal 21.14 20.01 4 9332 24 34947571
Blood creatinine abnormal 20.96 20.01 11 9325 2379 34945216

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haemolysis 488.36 16.12 154 14950 12658 79716626
Thrombotic microangiopathy 394.07 16.12 147 14957 20022 79709262
Haemoglobin decreased 279.51 16.12 272 14832 221847 79507437
Blood lactate dehydrogenase increased 238.75 16.12 126 14978 39044 79690240
Meningococcal sepsis 173.19 16.12 27 15077 59 79729225
Incorrect dose administered 148.37 16.12 120 14984 76510 79652774
Meningococcal bacteraemia 137.20 16.12 19 15085 8 79729276
Off label use 131.10 16.12 422 14682 906793 78822491
Haptoglobin decreased 118.09 16.12 31 15073 1316 79727968
Extravascular haemolysis 115.76 16.12 21 15083 144 79729140
Haemoglobinuria 113.42 16.12 27 15077 764 79728520
Platelet count decreased 107.82 16.12 157 14947 194507 79534777
Renal impairment 101.87 16.12 137 14967 157646 79571638
Reticulocyte count increased 98.39 16.12 27 15077 1359 79727925
Breakthrough haemolysis 91.02 16.12 13 15091 10 79729274
Suspected COVID-19 88.31 16.12 30 15074 3103 79726181
Chromaturia 85.66 16.12 56 15048 25690 79703594
Polyomavirus-associated nephropathy 84.83 16.12 34 15070 5593 79723691
Inappropriate schedule of product administration 84.66 16.12 115 14989 133513 79595771
Polyomavirus viraemia 79.71 16.12 24 15080 1683 79727601
Exposure during pregnancy 79.71 16.12 97 15007 101035 79628249
End stage renal disease 79.21 16.12 41 15063 12179 79717105
Renal transplant failure 77.09 16.12 24 15080 1883 79727401
Myasthenia gravis crisis 71.31 16.12 20 15084 1091 79728193
Meningitis meningococcal 70.01 16.12 13 15091 103 79729181
Atypical haemolytic uraemic syndrome 63.62 16.12 18 15086 1014 79728270
Meningococcal infection 63.36 16.12 12 15092 107 79729177
Toxicity to various agents 61.18 16.12 5 15099 421535 79307749
Gonorrhoea 60.91 16.12 13 15091 221 79729063
Arteriovenous fistula occlusion 59.60 16.12 15 15089 537 79728747
Haemoglobin abnormal 58.55 16.12 28 15076 7026 79722258
SARS-CoV-2 test positive 58.33 16.12 33 15071 11683 79717601
Condition aggravated 57.85 16.12 217 14887 500907 79228377
Poor venous access 56.79 16.12 38 15066 18111 79711173
Transplant rejection 56.77 16.12 39 15065 19398 79709886
Cytomegalovirus infection 54.85 16.12 53 15051 42591 79686693
Graft loss 54.52 16.12 16 15088 1027 79728257
Blue toe syndrome 53.72 16.12 14 15090 577 79728707
Complement factor increased 53.66 16.12 8 15096 11 79729273
Proteinuria 52.72 16.12 46 15058 32456 79696828
Drug interaction 52.52 16.12 8 15096 415175 79314109
Multiple organ dysfunction syndrome 49.85 16.12 85 15019 120161 79609123
Cervicitis 48.85 16.12 11 15093 242 79729042
Blood lactate dehydrogenase abnormal 47.90 16.12 11 15093 265 79729019
Nephrectomy 47.13 16.12 17 15087 2098 79727186
Epstein-Barr viraemia 46.44 16.12 17 15087 2188 79727096
Staphylococcal mediastinitis 44.74 16.12 8 15096 50 79729234
C3 glomerulopathy 43.71 16.12 8 15096 58 79729226
Dyspnoea exertional 43.50 16.12 67 15037 87006 79642278
Gonococcal infection 42.69 16.12 8 15096 67 79729217
Transfusion 42.49 16.12 34 15070 21296 79707988
Aplastic anaemia 41.01 16.12 31 15073 17874 79711410
Bacteraemia 40.72 16.12 40 15064 32784 79696500
Jaundice 40.11 16.12 50 15054 53299 79675985
Complement factor C3 decreased 39.47 16.12 10 15094 368 79728916
Graft versus host disease 38.88 16.12 28 15076 14998 79714286
Total complement activity decreased 37.86 16.12 5 15099 0 79729284
Total complement activity increased 37.86 16.12 5 15099 0 79729284
Drug hypersensitivity 37.23 16.12 6 15098 298910 79430374
Waterhouse-Friderichsen syndrome 35.51 16.12 5 15099 3 79729281
Blood creatinine increased 34.80 16.12 85 15019 154972 79574312
Budd-Chiari syndrome 34 16.12 7 15097 99 79729185
Renal transplant 33.64 16.12 14 15090 2533 79726751
Graft ischaemia 33.35 16.12 6 15098 39 79729245
Sepsis 32.94 16.12 119 14985 269309 79459975
Cytomegalovirus oesophagitis 32.56 16.12 10 15094 750 79728534
Cytomegalovirus gastrointestinal infection 31.87 16.12 9 15095 503 79728781
Drug intolerance 31.37 16.12 6 15098 264113 79465171
Fatigue 31.20 16.12 290 14814 929437 78799847
Iron overload 30.67 16.12 12 15092 1852 79727432
Endoscopy upper gastrointestinal tract abnormal 30.54 16.12 6 15098 66 79729218
Pre-eclampsia 30.19 16.12 18 15086 7023 79722261
Bone marrow transplant 29.89 16.12 11 15093 1437 79727847
Adenovirus infection 29.63 16.12 19 15085 8428 79720856
Kidney fibrosis 29.24 16.12 14 15090 3521 79725763
Rheumatoid arthritis 28.80 16.12 3 15101 208467 79520817
Haemolytic anaemia 28.45 16.12 25 15079 17795 79711489
Intravascular haemolysis 27.59 16.12 9 15095 821 79728463
Renal pain 27.47 16.12 18 15086 8278 79721006
Gastroenteritis 27.32 16.12 33 15071 34049 79695235
Renal tubular atrophy 27.23 16.12 11 15093 1845 79727439
Encephalitis viral 26.91 16.12 12 15092 2567 79726717
Complications of transplanted kidney 26.58 16.12 16 15088 6350 79722934
Hypertension 26.20 16.12 128 14976 330864 79398420
Haemolytic uraemic syndrome 26.19 16.12 14 15090 4435 79724849
Premature delivery 26.17 16.12 27 15077 23440 79705844
Disseminated varicella zoster virus infection 25.73 16.12 8 15096 625 79728659
Haematocrit abnormal 25.59 16.12 10 15094 1538 79727746
Device related infection 25.55 16.12 32 15072 34262 79695022
Babesiosis 25.43 16.12 7 15097 356 79728928
Plasmapheresis 25.29 16.12 8 15096 661 79728623
Viral sepsis 25.19 16.12 6 15098 170 79729114
Myelodysplastic syndrome 23.74 16.12 29 15075 30272 79699012
Arthritis bacterial 23.53 16.12 17 15087 9149 79720135
Small cell lung cancer recurrent 22.65 16.12 4 15100 23 79729261
Delayed engraftment 22.18 16.12 6 15098 286 79728998
Brain abscess 22.16 16.12 13 15091 4923 79724361
Red blood cell schistocytes present 22.09 16.12 7 15097 582 79728702
Pain 21.77 16.12 65 15039 703737 79025547
Mean cell volume increased 21.77 16.12 14 15090 6239 79723045
Glomerulonephritis membranoproliferative 21.70 16.12 7 15097 616 79728668
Hypervolaemia 21.52 16.12 33 15071 42657 79686627
Product dose omission issue 21.48 16.12 10 15094 247527 79481757
Pruritus 21.37 16.12 26 15078 394622 79334662
Therapeutic product effect decreased 21.05 16.12 3 15101 163860 79565424
Muscle strain 20.69 16.12 16 15088 9539 79719745
Serum ferritin increased 20.26 16.12 16 15088 9831 79719453
Neisseria infection 20.14 16.12 5 15099 169 79729115
Haematocrit decreased 19.88 16.12 39 15065 61273 79668011
Platelet count abnormal 19.73 16.12 12 15092 4850 79724434
SARS-CoV-2 test negative 19.68 16.12 8 15096 1363 79727921
Reperfusion injury 19.43 16.12 5 15099 196 79729088
Complement factor abnormal 19.42 16.12 3 15101 6 79729278
Pneumonia bacterial 19.35 16.12 21 15083 19310 79709974
Haptoglobin increased 19.07 16.12 5 15099 211 79729073
Laboratory test abnormal 19.05 16.12 25 15079 28023 79701261
Thrombosis 18.74 16.12 46 15058 84054 79645230
Haptoglobin abnormal 17.89 16.12 3 15101 12 79729272
Cholelithiasis 17.69 16.12 34 15070 52630 79676654
Kidney transplant rejection 17.62 16.12 15 15089 10231 79719053
Syncope 17.61 16.12 6 15098 179443 79549841
Febrile neutropenia 17.60 16.12 11 15093 230988 79498296
Headache 17.55 16.12 195 14909 653577 79075707
Anaemia 17.53 16.12 144 14960 444871 79284413
Pericarditis constrictive 17.52 16.12 6 15098 636 79728648
Escherichia urinary tract infection 17.43 16.12 17 15087 13808 79715476
Septic shock 17.39 16.12 57 15047 122744 79606540
Malignant atrophic papulosis 17.34 16.12 3 15101 15 79729269
Viral infection 17.27 16.12 30 15074 42986 79686298
Neuropathy peripheral 17.22 16.12 3 15101 141302 79587982
Confusional state 17.16 16.12 21 15083 317976 79411308
Osteomyelitis chronic 16.97 16.12 6 15098 698 79728586
Depression 16.97 16.12 10 15094 216780 79512504
Rash 16.75 16.12 55 15049 578303 79150981
Complement factor C4 decreased 16.68 16.12 5 15099 345 79728939
Escherichia bacteraemia 16.46 16.12 12 15092 6550 79722734
Meningitis 16.42 16.12 14 15090 9568 79719716
Pseudomonas infection 16.36 16.12 20 15084 20883 79708401
Alopecia 16.31 16.12 12 15092 231343 79497941

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA25 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA EPC N0000175575 Complement Inhibitor
MeSH PA D051056 Complement Inactivating Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
FDA MoA N0000175974 Complement Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Paroxysmal nocturnal hemoglobinuria indication 1963002 DOID:0060284
Neuromyelitis optica indication 25044007 DOID:8869
Refractory generalized myasthenia gravis indication 230686005
Congenital hemolytic uremic syndrome indication 444976001
Atypical hemolytic uremic syndrome indication 789660001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Complement C5 Secreted ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D03940 KEGG_DRUG
4026032 VUID
N0000179786 NUI
4026032 VANDF
CHEMBL1201828 ChEMBL_ID
C481642 MESH_SUPPLEMENTAL_RECORD_UI
6884 IUPHAR_LIGAND_ID
DB01257 DRUGBANK_ID
591781 RXNORM
108542 MMSL
23533 MMSL
d06673 MMSL
012087 NDDF
426801002 SNOMEDCT_US
427429004 SNOMEDCT_US
C1541483 UMLSCUI
8231 INN_ID
A3ULP0F556 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SOLIRIS HUMAN PRESCRIPTION DRUG LABEL 1 25682-001 INJECTION, SOLUTION, CONCENTRATE 300 mg INTRAVENOUS BLA 29 sections
SOLIRIS HUMAN PRESCRIPTION DRUG LABEL 1 25682-001 INJECTION, SOLUTION, CONCENTRATE 300 mg INTRAVENOUS BLA 29 sections